Fig. 3

Anti-tumor efficacy of DZD2269 in animal models in the presence or absence of T cells (A) B16F10 cells were inoculated in the back of C57BL/6 mice, and the mice were treated with DZD2269. Statistically significant difference was calculated by using two-way ANOVA (**** P: < 0.0001, ns: no significance). (B) C57BL/6 mice were treated with DZD2269 at 0.3, 3, 10, and 30 mg/kg bid for 4 days. On day 4, plasma was collected for PK analysis before dosing and at 0.5, 1, 2, 4, and 7 h after dosing. On the same day, whole blood was also collected before dosing for PD (pCREB) analysis. Cav, ss: average steady-state plasma drug concentration. (C-D) B16F10 cells were injected through tail vein on (C) C57BL/6 mice (n = 9) or (D) BALB/c nude mice (n = 8), lung metastatic nodes were counted at Day13. bid: twice daily. Statistically significant difference was calculated by using one-way ANOVA (*: p < 0.05; ns: no significance)